FPRT Bio Selected to Present at Cavendish Global Health Impact Forum

Forum Uniquely Brings Together Leading Family Offices and Their Foundations Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities within Health and Life Sciences

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

New York, NY (PRWEB) April 28, 2014

FPRT Bio, a clinical stage company developing a novel anti-inflammatory drug therapy for the treatment for neurodegenerative diseases including ALS, Parkinson’s and Alzheimer’s disease, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Michael Moffat, Cavendish co-founder and President explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of FPRT Bio research and scientific insights in neurodegenerative diseases including ALS, Parkinson’s and Alzheimer’s disease positions them to make a major contribution to treating the cause of these devastating neurologic diseases.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to attack chronic neuroinflammation, a major cause of neurodegenerative diseases such as ALS and Alzheimer’s disease. These devastating neurologic diseases have no cure, cause incalculable suffering by patients and place tremendous burdens on families and payers.” said RJ Tesi, MD, President and CEO. “We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

About FPRT Bio

FPRT Bio is developing XPro1595, a novel, second-generation, selective inhibitor of soluble TNF for the treatment of neurodegenerative diseases including ALS, Parkinson’s and Alzheimer’s disease. XPro1595 is a potent anti-inflammatory drug that crosses the blood-brain-barrier to decrease production of inflammatory cytokines by activated microglial cells and astrocytes. By polarizing the complex TNF biology of the brain to trans-membrane TNF effects, XPro1595 is neuroprotective, promotes remyelination and improves neuroplasticity. This unique biology and pharmacology makes XPro1595 ideally suited for treating these devastating neurologic diseases. FPRT Bio is raising a Series A to support Proof-of-Biology clinical trials in two indications – ALS and Alzheimer’s disease. FPRT Bio has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to research a novel therapeutic strategy to treat Parkinson’s disease.

Further information is available on the Company's website, http://www.fprtbio.com.

About Cavendish Global
(http://cavendishglobal.com)
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: http://cavendishglobal.com


Contact